{
    "nctId": "NCT06557057",
    "briefTitle": "Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk",
    "officialTitle": "Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk",
    "overallStatus": "RECRUITING",
    "conditions": "HER2-Positive Breast Carcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 75,
    "primaryOutcomeMeasure": "DI (disposition index)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Post-menopausal women with hormone receptor positive breast cancer. Post-menopause will be defined as women who experience 12 months of amenorrhea or have undergone bilateral salpingo-oophorectomy.\n\n  * 25 women who are planning to start or are within 6 months of starting treatment with aromatase inhibitors, after consultation in breast clinic and cancer center.\n  * 25 women who will be starting Tamoxifen (comparative group)\n  * 25 healthy post menopausal women will also be recruited.\n\nExclusion Criteria:\n\n* Established diagnosis of diabetes\n\n  * Therapy with medications that could affect glucose metabolism\n  * Screening fasting glucose \u2265 126 mg/dl, and/or HbA1c \u2265 6.5%\n  * History of upper GI surgery that alters gastric emptying or causing malabsorption e.g., bariatric surgery, fundoplication",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}